New drug trial targets rare, debilitating nerve disorder
Disease control
Not yet recruiting
This study is testing whether a drug called zanubrutinib can improve nerve function in people with a rare immune disorder called anti-MAG neuropathy. About 50 adults with confirmed diagnosis and measurable nerve disability will take the drug for 12 months to see if their neurolog…
Phase: PHASE2 • Sponsor: Azienda Ospedaliera di Padova • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC